Literature DB >> 19055511

Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus.

S Koulchitsky1, M J M Fischer, K Messlinger.   

Abstract

Infusion of nitric oxide (NO) donors is known to induce delayed attacks of migraine and cluster headache or aggravate tension-type headaches in patients suffering from these primary headaches. Previously we have reported that infusion of NO donors in the rat causes delayed neuronal activity in the spinal trigeminal nucleus, which parallels the above clinical observations. Suggesting that endogenous NO production is involved in the generation of primary headaches, we used this animal model of meningeal nociception to determine whether a prolonged increase in NO levels causes an increase in neuronal activity. In anaesthetized rats spinal trigeminal neurons with afferent input from the exposed dura were recorded. Continuous intravenous infusion of the NO donors sodium nitroprusside (25 microg/kg/h) or glycerol trinitrate (250 microg/kg/h) for 2 h induced a persisting increase in neuronal activity but no change in systemic blood pressure. In this activated trigeminal system the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS (900 microg/kg) was infused. Spinal trigeminal activity was significantly reduced within minutes and to a similar extent as previously reported in animals not treated with NO. Slow continuous NO infusion may be a model of the active headache phase, and inhibition of CGRP receptors can reverse the induced neuronal activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19055511     DOI: 10.1111/j.1468-2982.2008.01745.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  27 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

Review 2.  CGRP as a neuropeptide in migraine: lessons from mice.

Authors:  Andrew F Russo
Journal:  Br J Clin Pharmacol       Date:  2015-07-14       Impact factor: 4.335

Review 3.  CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?

Authors:  C S Walker; D L Hay
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 4.  Targeted Nitric Oxide Synthase Inhibitors for Migraine.

Authors:  Amynah A Pradhan; Zachariah Bertels; Simon Akerman
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 5.  Modelling headache and migraine and its pharmacological manipulation.

Authors:  S E Erdener; T Dalkara
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

6.  [Pain-relieving effect of CGRP antagonism on inflammatory pain].

Authors:  S Hirsch; F Birklein
Journal:  Schmerz       Date:  2014-10       Impact factor: 1.107

7.  Long-Term Depression Induced by Optogenetically Driven Nociceptive Inputs to Trigeminal Nucleus Caudalis or Headache Triggers.

Authors:  Bruno Pradier; Hye Bin Shin; Duk Soo Kim; Robyn St Laurent; Diane Lipscombe; Julie A Kauer
Journal:  J Neurosci       Date:  2018-07-27       Impact factor: 6.167

Review 8.  Migraine: where and how does the pain originate?

Authors:  Karl Messlinger
Journal:  Exp Brain Res       Date:  2009-03-14       Impact factor: 1.972

9.  Vascular extracellular signal-regulated kinase mediates migraine-related sensitization of meningeal nociceptors.

Authors:  XiChun Zhang; Vanessa Kainz; Jun Zhao; Andrew M Strassman; Dan Levy
Journal:  Ann Neurol       Date:  2013-06-17       Impact factor: 10.422

10.  Preclinical studies investigating the neural mechanisms involved in the co-morbidity of migraine and temporomandibular disorders: the role of CGRP.

Authors:  Simon Akerman; Marcela Romero-Reyes
Journal:  Br J Pharmacol       Date:  2020-10-21       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.